Skip to Main Content

Advertisement

Skip Nav Destination

Venetoclax Plus Carfilzomib: A New Wave of Myeloma Treatment

December 30, 2021

Luciano Costa, MD, talks about the combination of venetoclax and carfilzomib, which led to an 83% response rate in patients with relapsed and heavily-refractory myeloma.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X